Literature DB >> 21343441

Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin.

Carlo Tascini1, Antonello Di Paolo, Marialuisa Polillo, Mauro Ferrari, Paola Lambelet, Romano Danesi, Francesco Menichetti.   

Abstract

A 72-year-old man, receiving 8 mg daptomycin/kg body weight/day for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, was diagnosed with MRSA/vancomycin-resistant Enterococcus faecium (VRE) cholecystitis (daptomycin MIC values, 1 and 2 mg/liter, respectively). After the fifth drug dose, the bile concentration of daptomycin was 66 mg/liter 5 min after drug administration, with the biliary concentration/MIC values higher than 30 for both bacterial strains. Therefore, daptomycin achieved therapeutic levels in bile, hence suggesting a role for the drug in the treatment of MRSA/VRE cholecystitis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343441      PMCID： PMC3088188          DOI： 10.1128/AAC.01774-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Current and emerging serious Gram-positive infections.

Authors:  F Menichetti
Journal:  Clin Microbiol Infect       Date:  2005-05       Impact factor: 8.067

2.  A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.

Authors:  Marialuisa Polillo; Carlo Tascini; Marianna Lastella; Paolo Malacarne; Laura Ciofi; Bruno Viaggi; Guido Bocci; Francesco Menichetti; Romano Danesi; Mario Del Tacca; Antonello Di Paolo
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

3.  Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.

Authors:  Friederike Traunmüller; Michael V Schintler; Julia Metzler; Stephan Spendel; Oliver Mauric; Martin Popovic; Karl Heinz Konz; Erwin Scharnagl; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2010-04-07       Impact factor: 5.790

4.  Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis.

Authors:  Kathleen R Sheridan; Brian A Potoski; Ryan K Shields; Gerard J Nau
Journal:  Pharmacotherapy       Date:  2010-12       Impact factor: 4.705

5.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.

Authors:  M Shawn Riser; Christopher M Bland; Celeste N Rudisill; P Brandon Bookstaver
Journal:  Ann Pharmacother       Date:  2010-10-19       Impact factor: 3.154

Review 7.  Future trends in the treatment of serious Gram-positive infections.

Authors:  Rosemarie Metzger; Hugo Bonatti; Robert Sawyer
Journal:  Drugs Today (Barc)       Date:  2009-01       Impact factor: 2.245

8.  Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

Authors:  John F Mohr; Lawrence V Friedrich; Sara Yankelev; Kenneth C Lamp
Journal:  Int J Antimicrob Agents       Date:  2009-02-06       Impact factor: 5.283

9.  Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.

Authors:  Joseph S Bubalo; Myrna Y Munar; Ganesh Cherala; Brandon Hayes-Lattin; Richard Maziarz
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

10.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
  10 in total
  10 in total

1.  Persistent bacteraemia caused by Staphylococcus aureus in the gall bladder.

Authors:  Alexander Tin Han Yu; Tony Cun; Esther Benamu; Cybele Renault
Journal:  BMJ Case Rep       Date:  2017-11-08

2.  Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.

Authors:  Romain Garreau; Damien Montange; Antoine Grillon; François Jehl; Tristan Ferry; Laurent Bourguignon; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2022-08-16       Impact factor: 5.577

Review 3.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Successful treatment of methicillin-resistant Staphylococcus aureus bacteraemia and cholecystitis.

Authors:  Santosh Kumar Nepal; Smith Giri; Keshav Panday
Journal:  BMJ Case Rep       Date:  2012-10-06

Review 5.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

6.  Hiding in Fresh Fruits and Vegetables: Opportunistic Pathogens May Cross Geographical Barriers.

Authors:  Zahra S Al-Kharousi; Nejib Guizani; Abdullah M Al-Sadi; Ismail M Al-Bulushi; Baby Shaharoona
Journal:  Int J Microbiol       Date:  2016-02-16

7.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

8.  Draft genome sequence data of a clinical Enterococcus faecalis isolate SHH039 from a patient with cholecystitis from a tertiary care hospital in Sabah, Malaysia.

Authors:  Nur Nashyiroh Izayati Mastor; Vijay Kumar Subbiah; Wan Nazirah Wan Abu Bakar; Khurshida Begum; M Jahangir Alam; Mohammad Zahirul Hoque
Journal:  Data Brief       Date:  2022-03-06

9.  Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment.

Authors:  Lingling Ye; Xiang You; Jie Zhou; Chaohui Wu; Meng Ke; Wanhong Wu; Pinfang Huang; Cuihong Lin
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

10.  Spontaneous Bacterial Peritonitis Due to Methicillin-Resistant Staphylococcus Aureus in a Patient with Cirrhosis: The Potential Role for Daptomycin and Review of the Literature.

Authors:  Marco Falcone; Alessandro Russo; Giovanni Pacini; Manuela Merli; Mario Venditti
Journal:  Infect Dis Rep       Date:  2015-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.